Ticker >

Biocon share price

Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  211k   1k   224

305.85
0 0
BSE: 17 May 04:01 PM

Price Summary

Today's High

₹ 311.35

Today's Low

₹ 303.6

52 Week High

₹ 321.3

52 Week Low

₹ 217.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

36720.35 Cr.

Enterprise Value

37297.75 Cr.

No. of Shares

120.06 Cr.

P/E

307.79

P/B

3.37

Face Value

₹ 5

Div. Yield

0.16 %

Book Value (TTM)

₹  90.89

CASH

720.3 Cr.

DEBT

1297.7 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  0.99

Sales Growth

14.65%

ROE

30.29 %

ROCE

29.84%

Profit Growth

3208.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 25 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.65%
3 Year0.08%
5 Year-3.8%

Profit Growth

1 Year3208.25%
3 Year86.25%
5 Year64.22%

ROE%

1 Year30.29%
3 Year11.69%
5 Year9.32%

ROCE %

1 Year29.84%
3 Year12.08%
5 Year9.95%

Debt/Equity

0.1201

Price to Cash Flow

167.44

Interest Cover Ratio

43.6896551724138

CFO/PAT (5 Yr. Avg.)

0.331248759182053

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 60.64 0
Dec 2023 60.64 0
Sep 2023 60.64 0
Jun 2023 60.64 0
Mar 2023 60.64 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 86.8982585086848% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 43.6896551724138.
  • Company’s PEG ratio is 0.0959311634454547.
  • The company has an efficient Cash Conversion Cycle of 64.562497720392 days.
  • Company has a healthy liquidity position with current ratio of 3.67621776504298.
  • The company has a high promoter holding of 60.64%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 42.7839636427949.

 Limitations

  • The company has shown a poor revenue growth of 0.0753799468492522% for the Past 3 years.
  • Tax rate is low at 4.13301023155627.
  • The company is trading at a high EV/EBITDA of 83.5361.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 506.7 513.2 518.7 562.8 532.6
Total Expenditure 550.7 441.2 451.5 491.5 480.4
Operating Profit -44 72 67.2 71.3 52.2
Other Income 64 36 69.6 48.5 38.9
Interest 48.1 48.3 55 56 39.5
Depreciation 29.4 29.8 30.6 30.9 29.8
Exceptional Items 1853.6 19.7 -5.2 0 0
Profit Before Tax 1796.1 49.6 46 32.9 21.8
Tax -14.7 3 11.3 8.9 7.8
Profit After Tax 1810.8 46.6 34.7 24 14
Adjusted EPS (Rs) 15.08 0.39 0.29 0.2 0.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1785.7 1988.4 2028.4 1738.2 1992.9
Total Expenditure 1575.8 1706.5 1717.2 1677.1 1972.1
Operating Profit 209.9 281.9 311.2 61.1 20.8
Other Income 109.3 205.8 151.5 187.2 274.1
Interest 2.6 1.2 0.4 0.4 69.6
Depreciation 92.3 98 103.5 108.2 116.9
Exceptional Items 198.7 159.7 0 0 2862.8
Profit Before Tax 423 548.2 358.8 139.7 2971.2
Tax 44.7 111.9 78.3 53.6 122.8
Net Profit 492.7 440.9 280.5 86.1 2848.4
Adjusted EPS (Rs.) 3.15 3.64 2.34 0.72 23.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 300 600 600 600.3 600.3
Total Reserves 6815.4 6937.3 7307.1 7492.6 10315.7
Borrowings 1.4 0.7 0 75.9 1297.7
Other N/C liabilities -71.6 -134.7 -30 -10.7 95.4
Current liabilities 993.3 728 550.2 590.9 698
Total Liabilities 8038.5 8131.3 8427.3 8749 13007.1
Assets
Net Block 1059.2 720.7 728.6 804.7 899.4
Capital WIP 254.5 151.9 164.6 270.3 328.9
Intangible WIP 0 0 14.6 14.6 14.6
Investments 3979.7 4814 5073.4 5017.8 8949.8
Loans & Advances 180.7 280.9 150.5 154.2 159
Other N/C Assets 53 80.1 126.3 85.2 89.4
Current Assets 2511.4 2083.7 2169.3 2402.2 2566
Total Assets 8038.5 8131.3 8427.3 8749 13007.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 552.1 559.9 358.8 139.7 2971.2
Adjustment -111.8 -68.1 117.8 108.3 -2726.9
Changes in Assets & Liabilities -193.9 -14 156 -172 16.1
Tax Paid -136.9 -90.7 -61.3 -28.4 -41.1
Operating Cash Flow 109.5 387.1 571.3 47.6 219.3
Investing Cash Flow 315.3 -188.9 -720.6 -302.1 -1173.1
Financing Cash Flow -208.2 -128.9 27.8 112 1039.4
Net Cash Flow 216.6 69.3 -121.5 -142.5 85.6

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 60.64 60.64 60.64 60.64 60.64
dev mazumdar 0.08 0.08 0.08 0.08 0.08
glentec international 19.76 19.76 19.76 19.76 19.76
kiran mazumdar shaw 39.66 39.66 40.36 40.36 40.36
ravi rasendra mazumdar 0.44 0.44 0.44 0.44 0.44
j m m shaw 0.70 0.70 - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 39.36 39.36 39.36 39.36 39.36
arun suresh chandavarkar 1.10 1.10 1.10 1.10 1.10
beneficial holdings under... 0.46 0.46 0.46 0.46 0.46
investor education and pr... - 0.01 0.01 0.01 0.01
lici child fortune plus g... - - - - 4.41
quant mutual fund - quant... - - - - 1.24
sbi contra fund - - - - 2.74
icici prudential equity a... - - 1.22 1.99 -
lici ulip-growth fund 4.41 4.41 4.41 4.41 -
mirae asset large cap fun... - - 1.81 1.50 -
sbi healthcare opportunit... - - 1.79 2.86 -
aditya birla sun life tru... 1.37 1.43 - - -
icici prudential midcap 1... - 1.26 - - -
mirae asset balanced adva... - 2.11 - - -
icici prudential business... 1.49 - - - -
investor education and pr... 0.01 - - - -
mirae asset tax saver fun... 1.96 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Biocon reports 46% fall in Q4 consolidated net profit17 May 2024, 11:43AM Biocon - Quaterly Results16 May 2024, 5:16PM Biocon - Quaterly Results16 May 2024, 5:16PM Biocon informs about press release13 May 2024, 9:50AM Biocon signs exclusive distribution, supply agreement with Medix13 May 2024, 9:25AM Biocon informs about disclosure29 Apr 2024, 5:38PM Biocon informs about disclosure 20 Apr 2024, 2:30PM Biocon signs licensing and supply agreement with Biomm S.A.18 Apr 2024, 9:17AM Biocon’s arm transfers branded formulations business in India to Eris Lifesciences3 Apr 2024, 11:17AM Biocon informs about notification1 Apr 2024, 10:06AM Biocon informs about trading window closure28 Mar 2024, 5:20PM Biocon gets approval from MHRA, UK for complex formulation Liraglutide 28 Mar 2024, 9:39AM Biocon informs about newspaper advertisement23 Mar 2024, 9:33AM Biocon informs about loss of share certificate 16 Mar 2024, 2:38PM Biocon’s arm enters into long-term commercial collaboration with Eris Lifesciences15 Mar 2024, 2:09PM Biocon informs about disclosure 14 Mar 2024, 4:40PM Biocon informs about company statement4 Mar 2024, 9:55AM USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm1 Mar 2024, 9:53AM Biocon informs about disclosure29 Feb 2024, 5:13PM Biocon informs about analyst meet 27 Feb 2024, 11:33AM Biocon gets penalty of Rs 3.04 crore over GST-related issues24 Feb 2024, 2:43PM Biocon informs about analyst meet20 Feb 2024, 2:15PM Biocon included in S&P Global Sustainability Yearbook 2024 20 Feb 2024, 12:30PM Biocon reports consolidated net profit of Rs 753 crore in Q39 Feb 2024, 2:47PM Biocon informs about press release9 Feb 2024, 2:18PM Biocon informs about press release9 Feb 2024, 11:51AM Biocon’s arm enters into partnership with Sandoz 9 Feb 2024, 9:22AM Biocon - Quaterly Results8 Feb 2024, 7:08PM Biocon - Quaterly Results8 Feb 2024, 7:08PM Biocon gets tentative approval from USFDA for Dasatinib tablets 7 Feb 2024, 10:59AM Biocon informs about closure of trading window29 Dec 2023, 4:33PM Biocon’s arm inks pact with Sandoz 26 Dec 2023, 11:59AM Biocon informs about disclosure20 Dec 2023, 2:21PM Biocon informs about press release18 Dec 2023, 5:06PM Biocon’s arm acquires biosimilars business in around 120 countries18 Dec 2023, 4:45PM Biocon informs about press release15 Dec 2023, 3:24PM Biocon’s associate company completes $165 million Series C financing13 Dec 2023, 5:20PM Biocon’s arm completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe30 Nov 2023, 4:48PM Biocon - Quaterly Results10 Nov 2023, 4:24PM Biocon - Quaterly Results10 Nov 2023, 4:24PM Biocon’s arm divests BFI Non-Core Business to Eris Lifesciences10 Nov 2023, 2:41PM Biocon’s arm enters into definitive agreement with Eris Lifesciences 8 Nov 2023, 4:57PM USFDA issues official action indicated to Biocon arm's unit in Malaysia18 Oct 2023, 2:10PM Biocon informs about company statement18 Oct 2023, 9:51AM Biocon informs about analyst meet 11 Oct 2023, 10:01AM Biocon signs partnership agreement with Juno Pharmaceuticals6 Oct 2023, 4:27PM Biocon informs about analyst meet 22 Sep 2023, 10:10AM Biocon’s arm gets European Commission’s nod for YESAFILI20 Sep 2023, 5:11PM Biocon’s arm completes integration of Viatris’ biosimilars business in North America6 Sep 2023, 5:31PM Biocon’s arm acquires manufacturing facility of Eywa Pharma 2 Sep 2023, 2:37PM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Biocon cash from the operating activity was Rs 219.3 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.1201 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was 3208.43675916887 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 1.0437051532942 % which is a bad sign for profitability.
     
  • ROE: Biocon have a healthy ROE of 30.2934263562594 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Biocon is Rs 305.85. One can use valuation calculators of ticker to know if Biocon share price is undervalued or overvalued.
Last Updated on:
Brief about Biocon

Biocon Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Biocon Ltd. is a leading biopharmaceutical company in India that specializes in the development and manufacturing of biosimilars, novel biologics, and complex small molecules.  We will provide a comprehensive stock analysis of Biocon Ltd. for long-term stock investors.

Biocon Ltd. Share Price 

Biocon's share price has been performing well in recent years, with a steady growth trend. The company's share price is influenced by various factors such as market conditions, industry trends, and company-specific news. Ticker pre-built screening tools can help you keep track of Biocon's share price and compare it with its peers.

Biocon Ltd. Balance Sheet 

Biocon's balance sheet provides insights into the company's financial health and its ability to meet its financial obligations. Our premium features, such as DCF Analysis, BVPS Analysis, and DuPont analysis, can help you calculate the fair value of Biocon's stock based on its balance sheet. By analyzing the company's assets, liabilities, and equity, you can gain a better understanding of its financial position and make informed investment decisions.

Biocon Ltd. Annual Report 

Biocon's annual report provides a comprehensive overview of the company's financial performance, business strategy, and future outlook. You can download Biocon's annual reports from Ticker and analyze them to gain insights into the company's operations and growth prospects. 

Biocon Ltd. Dividend 

Biocon has a consistent track record of paying dividends to its shareholders. The company's dividend payout ratio and yield can provide insights into its financial health and growth prospects. By analyzing Biocon's dividend history and payout policies, you can make informed decisions about investing in the company's stock.

Biocon Ltd. Quarterly Results 

Biocon's quarterly results provide insights into its financial performance and growth prospects. Our premium features, such as earnings multiple approach and DuPont analysis, can help you analyze Biocon's quarterly results and calculate its fair value. By comparing Biocon's quarterly results with its peers and tracking its progress over time, you can make informed investment decisions.

Biocon Ltd. Stock Price 

Biocon's stock price is influenced by various factors such as market conditions, industry trends, and company-specific news. Our pre-built screening tools can help you keep track of Biocon's stock price and compare it with its peers. By analyzing Biocon's stock price trends and market conditions, you can make informed investment decisions.

Biocon Ltd. Price Chart 

Biocon's price chart provides a visual representation of its stock price trends over time. You can use our pre-built screening tools to analyze Biocon's price chart and compare it with its peers. By analyzing Biocon's price chart, you can gain insights into its stock price trends and make informed investment decisions.

Biocon Ltd. News 

Biocon's news provides insights into its business operations, growth prospects, and industry trends. You can use our pre-built screening tools to keep track of Biocon's news and analyze its impact on the company's stock price. By staying up-to-date with Biocon's news, you can make informed investment decisions.

Biocon Ltd. Concall Transcripts 

Biocon's concall transcripts provide insights into its management's views on the company's financial performance, business strategy, and future outlook. You can download Biocon's concall transcripts from Ticker and analyze them to gain insights into the company's operations and growth prospects. By analyzing Biocon's concall transcripts, you can make informed investment decisions.

Biocon Ltd. Investor Presentations 

Biocon's investor presentations provide insights into its business operations, growth prospects, and industry trends. You can download Biocon's investor presentations from Ticker and analyze them to gain insights into the company's operations and growth prospects. By staying up-to-date with Biocon's investor presentations, you can make informed investment decisions.

Biocon Ltd. Promoters 

Biocon's promoters are highly experienced professionals with a proven track record in the biopharmaceutical industry. By analyzing Biocon's promoters and their past performance, you can gain insights into the company's business operations and growth prospects. 

Biocon Ltd. Shareholders 

Biocon's shareholders are a diverse group of investors with different investment objectives and risk profiles. By analyzing Biocon's shareholders and their investment patterns, you can gain insights into the company's stock price trends and growth prospects.Ticker pre-built screening tools can help you compare Biocon's shareholders with its peers and track their progress over time.

 

 

Read More
X